11 results on '"Karita, Helen C Stankiewicz"'
Search Results
2. Simultaneous LC–MS/MS method for the quantitation of Azithromycin, Hydroxychloroquine and its metabolites in SARS-CoV-2(−/ +) populations using dried blood spots
- Author
-
Chhonker, Yashpal S., Aldhafiri, Wafaa N., Soni, Dhruvkumar, Trivedi, Neerja, Steinbronn, Claire, Johnson, Christine, Karita, Helen C. Stankiewicz, Paasche-Orlow, Michael K., Barnabas, Ruanne, Arnold, Samuel L., and Murry, Daryl J.
- Published
- 2023
- Full Text
- View/download PDF
3. Taking a stand against the politicization of medical research: how ‘swinging the pendulum’ poses a hazard to clinical trials, study participants, and the progress of science
- Author
-
Bershteyn, Anna, Schwartz, Mark D, Thorpe, Lorna E, Paasche-Orlow, Michael K, Kissinger, Patricia, Karita, Helen C Stankiewicz, Laufer, Miriam K, Hoffman, Risa M, Landovitz, Raphael J, Paolino, Kristopher, and Barnabas, Ruanne V
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Biomedical Research ,Clinical Trials as Topic ,Humans ,Hydroxychloroquine ,Patient Selection ,Politics ,COVID-19 Drug Treatment - Published
- 2021
4. Invasive Obstetric Procedures and Cesarean Sections in Women with Known Herpes Simplex Virus Status During Pregnancy
- Author
-
Karita, Helen C Stankiewicz, Moss, Nicholas J, Laschansky, Ellen, Drolette, Linda, Magaret, Amalia S, Selke, Stacey, Gardella, Carolyn, and Wald, Anna
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Prevention ,Infectious Diseases ,Preterm ,Low Birth Weight and Health of the Newborn ,Clinical Research ,Conditions Affecting the Embryonic and Fetal Periods ,Perinatal Period - Conditions Originating in Perinatal Period ,Contraception/Reproduction ,Pediatric Research Initiative ,Infant Mortality ,Sexually Transmitted Infections ,Pediatric ,Reproductive health and childbirth ,Infection ,Good Health and Well Being ,cesarean section ,genital herpes ,herpes simplex virus-2 ,pregnancy ,suppressive therapy ,Clinical sciences ,Medical microbiology - Abstract
BackgroundNeonatal herpes is a potentially devastating infection that results from acquisition of herpes simplex virus (HSV) type 1 or 2 from the maternal genital tract at the time of vaginal delivery. Current guidelines recommend (1) cesarean delivery if maternal genital HSV lesions are present at the time of labor and (2) antiviral suppressive therapy for women with known genital herpes to decrease HSV shedding from the genital tract at the time of vaginal delivery. However, most neonatal infections occur in infants born to women without a history of genital HSV, making current prevention efforts ineffective for this group. Although routine serologic HSV testing of women during pregnancy could identify women at higher risk of intrapartum viral shedding, it is uncertain how this knowledge might impact intrapartum management, and a potential concern is a higher rate of cesarean sections among women known to be HSV-2 seropositive.MethodsTo assess the effects of prenatal HSV-2 antibody testing, history of genital herpes, and use of suppressive antiviral medication on the intrapartum management of women, we investigated the frequency of invasive obstetric procedures and cesarean deliveries. We conducted a retrospective cohort study of pregnant women delivering at the University of Washington Medical center in Seattle, Washington. We defined the exposure of interest as HSV-2 antibody positivity or known history of genital herpes noted in prenatal records. The primary outcome was intrapartum procedures including fetal scalp electrode, artificial rupture of membranes, intrauterine pressure catheter, or operative vaginal delivery (vacuum or forceps). The secondary outcome was incidence of cesarean birth. Univariate and multivariable logistic regressions were performed.ResultsFrom a total of 449 women included in the analysis, 97 (21.6%) were HSV-2 seropositive or had a history of genital herpes (HSV-2/GH). Herpes simplex virus-2/GH women not using suppressive antiviral therapy were less likely to undergo intrapartum procedures than women without HSV-2/GH (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.25-0.95; P = .036), but this relationship was attenuated after adjustment for potential confounders (adjusted OR, 0.69; 95% CI, 0.34-1.41; P = .31). There was no difference in intrapartum procedures for women on suppressive therapy versus women without HSV-2/GH (OR, 1.17; 95% CI, 0.66-2.07; P = .60). Similar proportions of cesarean sections were performed within each group of women: 25% without history of HSV-2/GH, 30% on suppressive treatment, and 28.1% without suppressive treatment (global, P = .73).ConclusionsIn this single-site study, provider awareness of genital herpes infection either by HSV serotesting or history was associated with fewer invasive obstetric procedures shown to be associated with neonatal herpes, but it was not associated with an increased rate of cesarean birth.
- Published
- 2017
5. The Coronavirus Disease 2019 Pandemic Unmasked the Challenges Faced by Early-Stage Faculty in Infectious Diseases: A Call to Action.
- Author
-
Scherer, Erin M, Backer, Martin, Carvajal, Karen, Danziger-Isakov, Lara, Frey, Sharon, Howard, Leigh M, Huang, Felicia Scaggs, Kottkamp, Angelica C, Reid, Tara, Rodriguez-Barradas, Maria C, Karita, Helen C Stankiewicz, Teoh, Zheyi, Wald, Anna, Whitaker, Jennifer, Wiley, Zanthia, Ofotokun, Igho, Edwards, Kathryn M, and Group, for the Infectious Diseases Clinical Research Consortium (IDCRC) Mentorship Program Writing
- Subjects
PREVENTION of racism ,PREVENTION of employment discrimination ,DIVERSITY & inclusion policies ,COMMUNICABLE diseases ,CAREGIVERS ,VOCATIONAL guidance ,SEXISM ,SOCIAL support ,LABOR productivity ,MEDICAL school faculty ,LABOR demand ,EMPLOYEE recruitment ,WORK-life balance ,EXPERIENCE ,SEX distribution ,LABOR supply ,PSYCHOSOCIAL factors ,EMPLOYEES' workload ,AGING ,JOB satisfaction ,COVID-19 pandemic ,MEDICAL research ,EMPLOYEE retention - Abstract
The coronavirus disease 2019 (COVID-19) pandemic and associated increase in family care responsibilities resulted in unsustainable personal and professional workloads for infectious diseases (ID) faculty on the front lines. This was especially true for early-stage faculty (ESF), many of whom had caregiving responsibilities. In addition, female faculty, underrepresented in medicine and science faculty and particularly ESF, experienced marked declines in research productivity, which significantly impacts career trajectories. When combined with staffing shortages due to an aging workforce and suboptimal recruitment and retention in ID, these work-life imbalances have brought the field to an inflection point. We propose actionable recommendations and call on ID leaders to act to close the gender, racial, and ethnic gaps to improve the recruitment, retention, and advancement of ESF in ID. By investing in systemic change to make the ID workforce more equitable, we can embody the shared ideals of diversity and inclusion and prepare for the next pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Detection and Kinetics of Subgenomic Severe Acute Respiratory Syndrome Coronavirus 2 RNA Viral Load in Longitudinal Diagnostic RNA–Positive Samples.
- Author
-
Deming, Meagan E, Dong, Tracy Q, Agrawal, Vaidehi, Mills, Margaret G, Huang, Meei Li W, Greninger, Alexander L, Jerome, Keith R, Wener, Mark H, Paasche-Orlow, Michael K, Kissinger, Patricia, Luk, Alfred, Hoffman, Risa M, Stewart, Jenell, Kottkamp, Angelica C, Bershteyn, Anna, Chu, Helen Y, Karita, Helen C Stankiewicz, Johnston, Christine M, Wald, Anna, and Barnabas, Ruanne
- Abstract
While detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by diagnostic reverse-transcription polymerase chain reaction (RT-PCR) is highly sensitive for viral RNA, the nucleic acid amplification of subgenomic RNAs (sgRNAs) that are the product of viral replication may more accurately identify replication. We characterized the diagnostic RNA and sgRNA detection by RT-PCR from nasal swab samples collected daily by participants in postexposure prophylaxis or treatment studies for SARS-CoV-2. Among 1932 RT-PCR–positive swab samples with sgRNA tests, 40% (767) had detectable sgRNA. Above a diagnostic RNA viral load (VL) threshold of 5.1 log
10 copies/mL, 96% of samples had detectable sgRNA with VLs that followed a linear trend. The trajectories of diagnostic RNA and sgRNA VLs differed, with 80% peaking on the same day but duration of sgRNA detection being shorter (8 vs 14 days). With a large sample of daily swab samples we provide comparative sgRNA kinetics and a diagnostic RNA threshold that correlates with replicating virus independent of symptoms or duration of illness. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Self-Assessed Severity as a Determinant of Coronavirus Disease 2019 Symptom Specificity: A Longitudinal Cohort Study.
- Author
-
Bershteyn, Anna, Dahl, Angela M, Dong, Tracy Q, Deming, Meagan E, Celum, Connie L, Chu, Helen Y, Kottkamp, Angelica C, Greninger, Alexander L, Hoffman, Risa M, Jerome, Keith R, Johnston, Christine M, Kissinger, Patricia J, Landovitz, Raphael J, Laufer, Miriam K, Luk, Alfred, Neuzil, Kathleen M, Paasche-Orlow, Michael K, Pitts, Robert A, Schwartz, Mark D, and Karita, Helen C Stankiewicz
- Subjects
COVID-19 ,CONFIDENCE intervals ,SELF-evaluation ,SEVERITY of illness index ,DIARY (Literary form) ,SENSITIVITY & specificity (Statistics) ,LONGITUDINAL method ,EVALUATION - Abstract
Coronavirus disease 2019 symptom definitions rarely include symptom severity. We collected daily nasal swab samples and symptom diaries from contacts of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case patients. Requiring ≥1 moderate or severe symptom reduced sensitivity to predict SARS-CoV-2 shedding from 60.0% (95% confidence interval [CI], 52.9%−66.7%) to 31.5% (95% CI, 25.7%− 38.0%) but increased specificity from 77.5% (95% CI, 75.3%−79.5%) to 93.8% (95% CI, 92.7%−94.8%). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. LB-17. Efficacy of Hydroxychloroquine (HCQ) for Post-exposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Blinded, Randomized, Controlled Trial
- Author
-
Brown, Elizabeth R, primary, Bershteyn, Anna, additional, Karita, Helen C Stankiewicz, additional, Johnston, Christine, additional, Thorpe, Lorna, additional, Kottkamp, Angelica, additional, Neuzil, Kathleen, additional, Laufer, Miriam K, additional, Deming, Meagan, additional, Paasche-Orlow, Michael K, additional, Kissinger, Patricia J, additional, Luk, Alfred, additional, Paolino, Kristopher M, additional, Landovitz, Raphael J, additional, Hoffman, Risa, additional, Schaafsma, Torin, additional, Krows, Meighan L, additional, Thomas, Katherine, additional, Morrison, Susan, additional, Kidoguchi, Lara, additional, Wener, Mark H, additional, Greninger, Alexander L, additional, Huang, Meei-Li, additional, Jerome, Keith, additional, Wald, Anna, additional, Celum, Connie, additional, Chu, Helen Y, additional, and Baeten, Jared M, additional
- Published
- 2020
- Full Text
- View/download PDF
9. Humoral Response to HPV16 Proteins in Persons with Anal High-Grade Squamous Intraepithelial Lesion or Anal Cancer.
- Author
-
Karita, Helen C. Stankiewicz, Waterboer, Tim, Magaret, Amalia, Doody, David R., Pawlita, Michael, Brenner, Nicole, Galloway, Denise A., Wald, Anna, and Madeleine, Margaret M.
- Abstract
Background: This study was launched to evaluate the association of early and late antibodies to human papillomavirus 16 (HPV16) detection and risk of anal high-grade squamous intraepithelial lesions (HSIL) or cancer. Methods: We analyzed data from persons with anal HSIL or cancer and controls from a case-control study in Seattle, Washington. Sera were evaluated for HPV16 early (E1, E2, E4, E6, and E7) and late (L1) antibodies by multiplex serology. Logistic regression models were used to assess serologic associations with risk of anal HSIL or cancer. Results: The study included 67 participants with anal HSIL, 116 with anal cancer, and 830 population-based controls. HPV16 seropositivity to L1 [adjusted OR (aOR), 13.8; 95% confidence interval (CI), 7.4-25.8], E4 (aOR, 2.3; 95% CI, 1.1-4.5), and E6 (aOR, 4.9; 95% CI, 1.1-21.2) was associated with HSIL; and detection of all antibodies to HPV16 late and early proteins was associated with increased risk of anal cancer ranging from aOR 1.7 to 32.5 [L1 aOR, 12.5 (95% CI, 7.3-21.7); E1 aOR, 24.9 (95% CI, 10.3-59.9); E2 aOR, 6.3 (95% CI, 3.4-11.7); E4 aOR, 2.8 (95% CI, 1.6-4.8); E6 aOR, 32.5 (95% CI, 14.2-74.4); and E7 aOR, 1.7 (95% CI, 1.0-3.0)]. Conclusions: HPV serologic markers proved to be specific for identifying anal cancer. HPV16 E6 seropositivity is relatively uncommon in persons without anal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Maternal Hepatitis B Infection and Pregnancy Outcomes in the United States: A Population-Based Cohort Study.
- Author
-
Bajema, Kristina L, Karita, Helen C Stankiewicz, Tenforde, Mark W, Hawes, Stephen E, and Heffron, Renee
- Abstract
Background Hepatitis B virus (HBV) infection in pregnancy has been associated with risk of adverse maternal and infant outcomes in highly endemic settings, but this association is not well characterized in the United States. Methods We conducted a retrospective population-based cohort study in Washington State using linked birth certificate and hospital discharge records from 1992–2014. Among pregnant women with hepatitis B (n = 4391) and a hepatitis B–negative group (n = 22 410), we compared the risk of gestational diabetes, pre-eclampsia, eclampsia, placenta previa, preterm delivery, low birthweight, small for gestational age, and large for gestational age using multivariate logistic regression. Results Hepatitis B–infected pregnant women were more likely to be Asian (61% vs 8%, P <.001), foreign-born (76% vs 23%, P <.001), and older in age (77% vs 64% ≥26 years, P <.001). They were less commonly overweight or obese (33% vs 50%, P <.001). There was a lower risk of small for gestational age infants among HBV-infected women (adjusted RR [aRR], 0.79; 95% confidence interval [CI], 0.67–0.93). The risk of other adverse outcomes was not significantly different between hepatitis B–infected and –negative women (gestational diabetes: aRR, 1.11; 95% CI, 0.92–1.34; pre-eclampsia: aRR, 1.06; 95% CI, 0.82–1.35; eclampsia: aRR, 2.31; 95% CI, 0.90–5.91; placenta previa: aRR, 1.16; 95% CI, 0.35–3.84; preterm delivery: aRR, 1.15; 95% CI, 0.98–1.34; low birth weight: aRR, 1.08; 95% CI, 0.90–1.29; large for gestational age: aRR, 1.01; 95% CI, 0.82–1.24). Conclusions In a low-burden setting in the United States, hepatitis B infection was not associated with adverse pregnancy outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial.
- Author
-
Johnston C, Brown ER, Stewart J, Karita HCS, Kissinger PJ, Dwyer J, Hosek S, Oyedele T, Paasche-Orlow MK, Paolino K, Heller KB, Leingang H, Haugen HS, Dong TQ, Bershteyn A, Sridhar AR, Poole J, Noseworthy PA, Ackerman MJ, Morrison S, Greninger AL, Huang ML, Jerome KR, Wener MH, Wald A, Schiffer JT, Celum C, Chu HY, Barnabas RV, and Baeten JM
- Abstract
Background: Treatment options for outpatients with COVID-19 could reduce morbidity and prevent SARS-CoV-2 transmission., Methods: In this randomized, double-blind, three-arm (1:1:1) placebo-equivalent controlled trial conducted remotely throughout the United States, adult outpatients with laboratory-confirmed SARS-CoV-2 infection were recruited. Participants were randomly assigned to receive hydroxychloroquine (HCQ) (400 mg BID x1day, followed by 200 mg BID x9days) with or without azithromycin (AZ) (500 mg, then 250 mg daily x4days) or placebo-equivalent (ascorbic acid (HCQ) and folic acid (AZ)), stratified by risk for progression to severe COVID-19 (high-risk vs. low-risk). Self-collected nasal swabs for SARS-CoV-2 PCR, FLUPro symptom surveys, EKGs and vital signs were collected daily. Primary endpoints were: (a) 14-day progression to lower respiratory tract infection (LRTI), 28-day COVID-19 related hospitalization, or death; (b) 14-day time to viral clearance; secondary endpoints included time to symptom resolution (ClinicalTrials.gov: NCT04354428). Due to the low rate of clinical outcomes, the study was terminated for operational futility., Findings: Between 15th April and 27th July 2020, 231 participants were enrolled and 219 initiated medication a median of 5.9 days after symptom onset. Among 129 high-risk participants, incident LRTI occurred in six (4.7%) participants (two control, four HCQ/AZ) and COVID-19 related hospitalization in seven (5.4%) (four control, one HCQ, two HCQ/AZ); no LRTI and two (2%) hospitalizations occurred in the 102 low-risk participants (one HCQ, one HCQ/AZ). There were no deaths. Among 152 participants with viral shedding at enrollment, median time to clearance was 5 days (95% CI=4-6) in HCQ, 6 days (95% CI=4-8) in HCQ/AZ, and 8 days (95% CI=6-10) in control. Viral clearance was faster in HCQ (HR=1.62, 95% CI=1.01-2.60, p = 0.047) but not HCQ/AZ (HR=1.25, p = 0.39) compared to control. Among 197 participants who met the COVID-19 definition at enrollment, time to symptom resolution did not differ by group (HCQ: HR=1.02, 95% CI-0.63-1.64, p = 0.95, HCQ/AZ: HR=0.91, 95% CI=0.57-1.45, p = 0.70)., Interpretation: Neither HCQ nor HCQ/AZ shortened the clinical course of outpatients with COVID-19, and HCQ, but not HCQ/AZ, had only a modest effect on SARS-CoV-2 viral shedding. HCQ and HCQ/AZ are not effective therapies for outpatient treatment of SARV-CoV-2 infection., Funding: The COVID-19 Early Treatment Study was funded by the Bill & Melinda Gates Foundation (INV-017062) through the COVID-19 Therapeutics Accelerator. University of Washington Institute of Translational Health Science (ITHS) grant support (UL1 TR002319), KL2 TR002317, and TL1 TR002318 from NCATS/NIH funded REDCap. The content is solely the responsibility of the authors and does not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. PAN and MJA were supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program. Trial registration ClinicalTrials.gov number NCT04354428., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.